A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy

Autor:	Ignace Vergote, Kathleen N. Moore, Dana M. Chase, Robert L. Coleman, John Balser, Paul DiSilvestro, Ofer Lavie, Gilles Freyer, Klaus Baumann, Floor J. Backes, Antonio González-Martín, Shefali Agarwal, Bradley J. Monk, Mathias Fehr, Thomas J. Herzog, Bhavana Pothuri, Domenica Lorusso, Roisin E. O'Cearbhaill, Mansoor Raza Mirza
Rok vydání:	2016
Předmět:	0301 basic medicine Cancer Research Chemotherapy Advanced ovarian cancer business.industry medicine.medical_treatment Synthetic lethality Highly selective Double blind 03 medical and health sciences 030104 developmental biology 0302 clinical medicine PARP1 Oncology Homologous Recombination DNA Repair 030220 oncology & carcinogenesis medicine Cancer research In patient business
Zdroj:	Journal of Clinical Oncology. 34:TPS5606-TPS5606
ISSN:	1527-7755 0732-183X
Popis:	TPS5606Background: Niraparib is a highly selective PARP1/2 inhibitor that induces synthetic lethality in tumor cells with homologous recombination DNA repair deficiencies (HRD). Niraparib is admini...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5316d6556dc6cfbadffe551573d33496 https://doi.org/10.1200/jco.2016.34.15_suppl.tps5606 Zobrazit plný text záznamu